Fu X, Tan J, Sun C G, Leng H J, Xu Y S, Song C L
Departments of Orthopedics (X.F., J.T., C.G.S., H.J.L., and C.L.S.) and Neurology (Y.S.X.), Peking University Third Hospital, Beijing, People's Republic of China.
Beijing Key Laboratory of Spinal Diseases, Beijing, People's Republic of China.
J Bone Joint Surg Am. 2016 Nov 16;98(22):1924-1932. doi: 10.2106/JBJS.15.00937.
Osteoporosis leads to poor osseointegration and reduces implant stability. Statins have been found to stimulate bone formation, but the bioavailability from oral administration is low. Local application may be more effective at augmenting bone formation and enhancing implant stability. This study was performed to evaluate the efficacy of an intraosseous injection of simvastatin in thermosensitive poloxamer 407 hydrogel to enhance pedicle-screw fixation in calcium-restricted ovariectomized minipigs.
Nine mature female Guangxi Bama minipigs underwent bilateral ovariectomy and were fed a calcium-restricted diet for 18 months. Simvastatin (0, 0.5, or 1 mg) in thermosensitive poloxamer 407 hydrogel was injected into the lumbar vertebrae (L4-L6), and titanium alloy pedicle screws were implanted. Bone mineral density (BMD) measurements of the lumbar vertebrae were determined by dual x-ray absorptiometry (DXA) before and 3 months after treatment. The lumbar vertebrae were harvested and analyzed with use of microcomputed tomography, biomechanical pull-out testing, histological analysis, and Western blot analysis for bone morphogenetic protein (BMP)-2 and vascular endothelial growth factor (VEGF) expression.
Evaluation over a 3-month study period demonstrated that the BMD of the vertebrae injected with 0.5 and 1.0 mg of simvastatin had increased by 31.25% and 31.09%, respectively, compared with vehicle-only injection (p ≤ 0.00014 for both) and increased by 32.12% and 28.16%, respectively, compared with the pre-treatment levels (p < 0.0001 for both). A single injection of simvastatin in poloxamer 407 increased trabecular volume fraction, thickness, and number and decreased trabecular separation (p ≤ 0.002). The bone formation and mineral apposition rates significantly increased (p ≤ 0.023). The percentage of osseointegration in the simvastatin 0.5 and 1-mg groups was 46.54% and 42.63% greater, respectively, than that in the vehicle-only group (p ≤ 0.006), and the maximum pull-out strength was 45.75% and 51.53% greater, respectively, than in the vehicle-only group (p ≤ 0.0005). BMP-2 and VEGF expressions were higher than for the vehicle-only injection.
A single intraosseous injection of simvastatin in thermosensitive poloxamer 407 hydrogel stimulated bone formation, increased BMD, improved bone microstructure, promoted osseointegration, and significantly enhanced the stability of pedicle screws in calcium-restricted ovariectomized minipigs.
These results provide rationale for evaluating intraosseous injection of simvastatin in poloxamer 407 to enhance implant fixation in patients with osteoporosis.
骨质疏松症会导致骨整合不良并降低植入物稳定性。已发现他汀类药物可刺激骨形成,但口服给药的生物利用度较低。局部应用在促进骨形成和增强植入物稳定性方面可能更有效。本研究旨在评估在热敏泊洛沙姆407水凝胶中骨内注射辛伐他汀以增强钙限制型去卵巢小型猪椎弓根螺钉固定效果的疗效。
9只成年雌性广西巴马小型猪接受双侧卵巢切除术,并给予钙限制饮食18个月。将热敏泊洛沙姆407水凝胶中的辛伐他汀(0、0.5或1毫克)注入腰椎(L4-L6),并植入钛合金椎弓根螺钉。在治疗前和治疗后3个月通过双能X线吸收法(DXA)测定腰椎的骨密度(BMD)。采集腰椎并使用微型计算机断层扫描、生物力学拔出试验、组织学分析以及对骨形态发生蛋白(BMP)-2和血管内皮生长因子(VEGF)表达进行蛋白质印迹分析。
在为期3个月的研究期间进行的评估表明,与仅注射载体相比,注射0.5毫克和1.0毫克辛伐他汀的椎骨BMD分别增加了31.25%和31.09%(两者p≤0.00014),与治疗前水平相比分别增加了32.12%和28.16%(两者p<0.0001)。在泊洛沙姆407中单次注射辛伐他汀可增加小梁体积分数、厚度和数量,并减少小梁间距(p≤0.002)。骨形成和矿物质沉积率显著增加(p≤0.023)。0.5毫克和1毫克辛伐他汀组的骨整合百分比分别比仅注射载体组高46.54%和42.63%(p≤0.006),最大拔出强度分别比仅注射载体组高45.75%和51.53%(p≤0.0005)。BMP-2和VEGF表达高于仅注射载体组。
在热敏泊洛沙姆407水凝胶中单次骨内注射辛伐他汀可刺激骨形成,增加BMD,改善骨微结构,促进骨整合,并显著增强钙限制型去卵巢小型猪椎弓根螺钉的稳定性。
这些结果为评估在泊洛沙姆407中骨内注射辛伐他汀以增强骨质疏松症患者的植入物固定提供了理论依据。